Advisers to the Centers for Disease Control and Prevention voted Tuesday to endorse emergency authorization of a new COVID-19 vaccine developed by the Maryland biotechnology company Novavax, making it the fourth immunization to clear that hurdle in the U.S. — and the first to rely on the same familiar technology as some seasonal flu shots.

An advisory panel to the Food and Drug Administration previously recommended making two doses of Novavax available to Americans 18 and older for their initial inoculation, and CDC Director Rochelle Walensky is expected to sign off on the new vaccine later this week — after which the Biden administration’s recently announced order of 3.2 million